- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,201GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,201GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2024
- 200 Pages
Global
From €2407EUR$2,490USD£2,068GBP
- Report
- March 2024
- 238 Pages
Global
From €7686EUR$7,950USD£6,602GBP
- Report
- August 2023
- 85 Pages
United States
From €4592EUR$4,750USD£3,945GBP
- Report
- October 2022
- 180 Pages
Europe
From €5752EUR$5,950USD£4,941GBP
- Report
- February 2022
- 149 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- January 2024
- 97 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- May 2023
- 147 Pages
Global
From €5800EUR$5,999USD£4,982GBP
Trimethoprim is a urological disorder drug used to treat a variety of urinary tract infections. It is a synthetic antibacterial agent that works by inhibiting the production of dihydrofolic acid, which is necessary for bacterial growth. It is often used in combination with sulfamethoxazole to treat infections caused by bacteria. Trimethoprim is available in both oral and intravenous forms and is generally well tolerated. Common side effects include nausea, vomiting, and diarrhea.
Trimethoprim is a widely used drug in the urological disorder market, as it is effective in treating a variety of urinary tract infections. It is often prescribed in combination with other drugs to treat more severe infections. It is also used to prevent urinary tract infections in patients who are at risk of developing them.
Some companies in the trimethoprim market include Pfizer, Merck, GlaxoSmithKline, and AstraZeneca. Show Less Read more